Publication | Closed Access

First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial

Neuro-oncologyMedicineFirst-line ZorifertinibCancer GrowthPathologyBronchial NeoplasmCancer TreatmentOncologyCell BiologyLung CancerMolecular OncologyPhase 3Everest Trial